Havana, May 6 (Prensa Latina) Cuba guarantees the production of national drugs that are used in the protocols to treat Covid-19, Molecular Immunology Center (CIM) Director Eduardo Ojito said on Tuesday.
Three medications made by the CIM have proved to be effective against the pandemic caused by the SARS-Cov-2 coronavirus and give hope to both Cuban patients and many people who are sick in the world, the expert said at the Mesa Redonda (Round Table) TV and radio program.
The Itolizumab monoclonal antibody, which was created to fight leukemia and lymphomas, is administered in the third stage of Covid-19 to patients who are seriously and critically ill, because it is an immune modulator.
According to CIM Clinical Director Tania Crombet, the protocol on that drug started on March 27 and patients have been treated in ten hospitals in nine Cuban provinces.
Although the research has not concluded, preliminary data are encouraging. A high number of patients have left intensive care units and even hospitals, and efforts are being made to complete the information, especially its effect on respiratory distress and on imaging and gasometrical parameters, she noted.
The other CIM products against Covid-19 are recombinant human erythropoietin, which has been administered for two decades to patients suffering from kidney insufficiency and anemia, and Leucocin, which generates stem cells, a research that is being carried out in conjunction with the Hematology Institute.